# Smith & Nephew plc (SNN)

> Source: Nexqual · https://nexqual.com/SNN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Smith & Nephew plc (SNN), nexqual.com/SNN" · informational, not investment advice.

**Price:** USD 30.88 (+5.64% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 29.23 · day 29.6–30.88 · 52w 26.12–37.09 · market cap $12.9B · NYQ

## Key facts
- 1 of 80 tracked superinvestors hold SNN (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Hold (mean 2.67 on a 1–5 scale) (6 analysts), mean target USD 32.32 (range 29–38).
- Total return with dividends: 1Y -13.1% vs S&P 500 +14.9%; 5Y -0.9% vs S&P 500 +80.3%.
- Next earnings: 2026-08-04, EPS estimate USD 0.53, revenue estimate $1.56B.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold SNN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Sarah Ketterer | Causeway Capital Management | 0.49% | $45.1M | Added +64.2% |

## Analysts
Consensus Hold (mean 2.67 on a 1–5 scale), 6 analysts; mean target USD 32.32 (low 29, high 38).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-31 | BTIG | Initiated | Neutral |  |
| 2026-08-06 | JP Morgan | Downgrade | Overweight → Neutral |  |
| 2026-08-05 | Barclays | Downgrade | Equal-Weight → Underweight |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -13.1% | -0.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -13.1% | -0.2% |
| Volatility (annualized) | 29.0% | 26.6% |
| Max drawdown | -27.1% (Nov 2025→Oct 2026) | -38.4% (Nov 2021→Sep 2022) |

## Peers (Medical Devices)
PEN (Penumbra, Inc.) USD 324.96 +0.43% · GMED (Globus Medical, Inc.) USD 81.66 +3.79% · GKOS (Glaukos Corporation) USD 176.69 -0.09% · PODD (Insulet Corporation) USD 148.12 +4.38% · BIO (Bio-Rad Laboratories, Inc.) USD 363.5 +0.83% · TXG (10x Genomics, Inc.) USD 69.75 -7.73%

## More
Full page: https://nexqual.com/SNN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name SNN in their own reports (relationship from SNN's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | MATERIALISE NV (MTLS) | 20-F 2026-04-23 | "In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc., or Zimmer Biomet, as well as with Enco…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.53 | $0.00 | — | $1.56B | 1 |
| Next quarter (ends 2026-12-31) | $0.71 | $0.00 | — | $1.81B | 1 |
| Current fiscal year (ends 2026-12-31) | $2.22 | $2.05 | +8.5% | $6.47B | 4 |
| Next fiscal year (ends 2027-12-31) | $2.41 | $2.28 | +5.5% | $6.80B | 4 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 81.1% | ±18.0% |
| 2026-12-18 | 56 | 51.1% | ±9.7% |
| 2027-03-19 | 147 | 28.2% | ±11.3% |
| 2027-06-17 | 237 | 25.7% | ±16.2% |